Originally published In Press as doi:10.1074/jbc.M110380200 on February 26, 2002
J. Biol. Chem., Vol. 277, Issue 19, 16576-16584, May 10, 2002
RhoA and Rho Kinase-dependent Phosphorylation of
Moesin at Thr-558 in Hippocampal Neuronal Cells by Glutamate*
Songhee
Jeon
,
Sohee
Kim
,
Jong-Bae
Park§,
Pann-Ghill
Suh§,
Yong Sik
Kim¶,
Chang-Dae
Bae
, and
Joobae
Park
From the
Department of Molecular Cell Biology,
Samsung Biomedical Research Institute, Sungkyunkwan University School
of Medicine, Suwon 440-746, Korea, the § Department of Life
Science, Pohang Institute of Technology and Sciences, Pohang 790-784, Korea, and the ¶ Department of Psychiatry, Seoul National
University College of Medicine, Seoul 110-744, Korea
Received for publication, October 29, 2001, and in revised form, February 19, 2002
 |
ABSTRACT |
When we were studying phosphorylated proteins in
the rat brain after electroconvulsive shock (ECS), we observed the
rapid phosphorylation of a 75-kDa protein, which cross-reacted with the
anti-phospho-p70 S6 kinase antibody. The phosphorylated protein was
purified and identified as moesin, a member of the ezrin/radixin/moesin (ERM) family and a general cross-linker between cortical actin filaments and plasma membranes. The purified moesin from rat brain was
phosphorylated at serine and threonine residues. Moesin was rapidly
phosphorylated at the threonine 558 residue after ECS in the rat
hippocampus, peaked at 1 min, and returned to the basal level by 2 min
after ECS. To investigate the mechanism of moesin phosphorylation in
neuronal cells, we stimulated a rat hippocampal progenitor cell,
H19-7/IGF-IR, with glutamate, and observed the increased
phosphorylation of moesin at Thr-558. Glutamate transiently activated
RhoA, and constitutively active RhoA increased the basal level
phosphorylation of moesin. The inhibition of RhoA and its effector, Rho
kinase, abolished increased Thr-558 phosphorylation by glutamate in
H19-7/IGF-IR cells, suggesting that the phosphorylation of moesin at
Thr-558 in H19-7/IGF-IR cells by glutamate is mediated by RhoA and Rho
kinase activation.
 |
INTRODUCTION |
Electroconvulsive shock
(ECS)1 has been used for the
treatments of psychiatric disorders such as depression, schizophrenia, and manic-depressive illness. Although the mechanism of the treatment has not been elucidated, recent progress in the cellular and molecular biology of neuronal tissues has enabled neuronal functions to be linked
to the regulation of gene expression and intracellular signal
transduction (1). Previously, we reported (4) that ECS induces
the expressions of various immediate early genes such as
c-fos, junB, and TiS-8 and that it
suppresses the expression of inositol 1,4,5-triphosphate kinase
and inositol 1,4,5-triphosphate receptor genes. We also observed (2-5,
7) that ECS caused the phosphorylation of many signaling molecules,
including those in the Pyk2-Ras-Raf-MEK-ERK pathway, and of
stress-signaling pathways in various rat brain regions.
Earlier we reported that ECS induces the phosphorylation of CREB in the
rat hippocampus (6). Several protein kinases have been suggested to be
CREB kinases in neuronal tissues, and we looked for protein kinases
potentially responsible for CREB phosphorylation. When we were studying
the phosphorylation of one of the suggested CREB kinases, ribosomal S6
kinase (S6K), we observed that a 75-kDa protein in the rat hippocampus
was rapidly phosphorylated after ECS. This was detected by an antibody
specific to phospho-p70 S6K. The protein was not detected by the
anti-p70 S6K antibody, suggesting that this protein was detected
nonspecifically by an anti-phospho-p70-S6K antibody. So we purified and
identified this protein as moesin (membrane-organizing extension spike
protein), a member of the ezrin/radixin/moesin (ERM) family of
proteins. ERM proteins consist of three domains: 1) a globular domain
at the N-terminal half, which is conserved among the members of the band 4.1 superfamily and is referred to as the FERM (4.1 and ERM) domain, a membrane-binding domain; followed by 2) an
extended
-helical domain; and 3) a charged C-terminal domain, which
includes a consensus sequence motif for actin binding. Thus, ERM
proteins have been suggested to function as cross-linkers between actin filaments and plasma membranes and to be involved in the formation of
microvilli, cell adhesion sites, ruffling membranes, and cleavage furrows (8-13).
The ERM proteins are phosphorylated in growth factor-stimulated cells
(14, 15). In thrombin-activated platelets, moesin is phosphorylated at
a specific C-terminal 558 threonine residue (Thr-558), causing
filopodia formation (16). In vitro functional analysis
suggested that C-terminal threonine phosphorylation maintains ERM
proteins in the active state by suppressing intramolecular interaction
(17).
RhoA is a member of the Ras-like GTPase superfamily and has been shown
to regulate the actin cytoskeleton and mitogenic signaling in response
to extracellular signals (18). In fibroblasts, ERM proteins were
phosphorylated and relocalized to apical membrane/actin protrusions in
a RhoA-dependent manner (19), and in Swiss 3T3 cells at
least one of the ERM proteins was shown to be required for the
RhoA-dependent formation of stress fibers and focal
contacts (20). RhoA has been reported to activate several
serine/threonine kinases such as ROK/ROCK-II/Rho kinase, ROK/ROCK-I,
citron kinase, protein kinase N, and protein kinase C1 (20). Rho
kinase effectively phosphorylates moesin at Thr-558 in vivo,
and this phosphorylation plays a crucial role in the formation of
microvilli-like structures (21).
During development and regeneration, neurons grow over large distances
in a process controlled by extrinsic factors and cytoskeletal interaction. The suppression of radixin and moesin altered growth cone
morphology, motility, and process formation in primary cultured neurons
(29). In addition, functional studies have established that in
sympathetic neurons, growth cone collapse induced by nerve growth
factor deprivation is concomitant with a significant decrease of the
radixin staining of growth cones (22). Taken together, these
observations suggest that localization of the ERM protein may be
essential for the normal expression of growth cone morphology. However,
the phosphorylation of ERM proteins in neuron tissues and cells has not
been studied, and it is also unknown whether ERM proteins, including
moesin, are involved in neuronal cell cytoskeletal changes. We
identified moesin as a protein that showed increased phosphorylation
after ECS in the rat brain and report that glutamate induces the
phosphorylation of moesin through the activation of RhoA and Rho kinase
in rat hippocampal neuronal cells.
 |
EXPERIMENTAL PROCEDURES |
Treatment of Animals and the Preparation of Hippocampal
Lysates--
Male Sprague-Dawley rats ranging from 150 to 200 g
were used in this study. Animals were treated in accordance with
National Institutes of Health guidelines for the care and use of
laboratory animals. ECS was administered (130 V, 0.5 s) via an ear
electrode. Control animals were treated in the same manner as the
ECS-treated animals but without the electric current. The animals were
decapitated at the prescribed times (0, 1, 2, 5, 10, 30, and 60 min
after ECS), and hippocampi were removed onto ice and homogenized
immediately with a glass Teflon homogenizer in 10 volumes of ice-cold
homogenization buffer (25 mM Tris, pH 7.5, 1 mM
EGTA, 2 mM EDTA, 50 mM NaF, 1 mM
Na3VO4, 10 mM sodium pyrophosphate,
0.2% Nonidet P-40, 1 mM PMSF, 1 mM DTT, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 10 µg/ml pepstatin) and
centrifuged for 10 min at 10,000 × g, 4 °C. The
protein samples were prepared by boiling the supernatant with 3×
Laemmli's sampling buffer. Protein was quantitatively assayed using
bicinchoninic acid (Sigma) or Bradford reagent (Bio-Rad).
Purification of the 75-kDa Protein--
Thirty rat brains,
dissected 1 min after ECS, were homogenized in buffer A (25 mM Tris, pH 7.5, 1 mM EGTA, 2 mM
EDTA, 50 mM NaF, 1 mM
Na3VO4, 10 mM sodium pyrophosphate,
1 mM PMSF, 1 mM DTT, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 10 µg/ml pepstatin) at a ratio of 5 ml/g of
brain, wet weight. The homogenate was centrifuged for 30 min at 20,000 rpm in a Beckman rotor, and the resulted supernatant was loaded at the
speed of 3 ml/min to 100 ml of packed DEAE-Sepharose (Amersham
Biosciences) equilibrated in buffer A. The column was washed with 100 ml of buffer A. The eluted and washed fractions were pooled and applied
to a 40-ml SP-Sepharose fast flow column (Amersham Biosciences)
equilibrated in buffer A at a speed of 2 ml/min. The column was washed
with 250 ml of 50 mM NaCl/buffer A and then eluted with 100 ml of 500 mM NaCl/buffer A. Fractions of 4 ml were
collected. The fractions containing enriched 75-kDa protein were pooled
and dialyzed against buffer A overnight at 4 °C. After
centrifugation, the pooled sample was applied to a 20-ml column of
heparin-Sepharose (Amersham Biosciences). The column was washed with
100 ml of buffer A and eluted with a NaCl gradient (0-500
mM). The 75-kDa protein was eluted between 100 and 200 mM NaCl. The eluant was dialyzed against buffer A, filtered
through a 0.22-µM membrane, and applied at 1 ml/min to a
Mono-Q HR 5/5 column (Amersham Biosciences) equilibrated with buffer A. The column was washed with 5 ml of buffer A, and the 75-kDa protein was
eluted as flow-through and washed out fractions. The eluant was
concentrated with a Centricon 50 (Amicon) for glycerol gradients.
Aliquots (200 µl) were loaded onto 5 ml of a glycerol gradient
mixture (from 15 to 35% glycerol/buffer A and 500 mM NaCl)
and centrifuged for 24 h at 47,000 rpm in a Beckman SW 55Ti rotor.
Elution was carried out with a Beckman recovery system and 11 drops
were collected per fraction. To obtain a single band of the 75-kDa
protein, preparative gel electrophoresis (Bio-Rad) was carried out at a
flow rate of 0.1 ml/min, and 200 µl each were collected per fractions.
The presence of 75-kDa protein was determined by immunoblotting with an
anti-phospho-p70 S6 kinase antibody, and the protein amount was
estimated by Bradford reagent and gel staining with Coomassie Brilliant
Blue R-250.
Immunoprecipitation and Immunoblotting--
Samples containing 1 mg of the hippocampal lysates were precleared with 50 µl of protein
A-Sepharose (Pierce) for 1 h. After preclearing, each lysate was
incubated with 20 µl of anti-moesin monoclonal antibody (BD
Transduction Laboratories) and 50 µl of protein A-Sepharose for
1 h, and the resulting immune complexes were pelleted at
10,000 × g and washed three times in homogenization buffer. Sample buffer (3×) was added, and samples were incubated at
100 °C for 5 min. 80 mg of the hippocampal lysates and 20 µg of
the cell lysates or immunoprecipitates were then electrophoresed in 8 or 12% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The membranes were incubated with anti-phospho-p70 S6 kinase
(Thr-421/Ser-424) (New England Biolabs), anti-moesin polyclonal (Santa
Cruz Biotechnology), anti-phosphothreonine and anti-phosphoserine
(Zymed Laboratories Inc.), anti-RhoA (Santa Cruz
Biotechnology), anti-Myc (provided by Prof. M. Han of Sungkyunkwan University, Suwon, Korea) and anti-phospho-ERM (297S) antibodies (kindly provided by Dr. S. Tsukita of Kyoto University, Kyoto, Japan)
for 2 h at room temperature. After washing with Tris-buffered saline/Tween (0.05%), the blots were incubated with horseradish peroxidase-conjugated anti-rabbit, anti-rat, or anti-mouse IgGs, and
the bands were visualized using the ECL system (Pierce). Molecular weights were determined by comparing the mobilities of the protein bands with prestained molecular weight markers (Invitrogen).
Protein Sequence Analysis--
One microgram of purified 75-kDa
protein was electrophoresed in 8% SDS-PAGE and stained with Coomassie
Blue. The two stained bands were separately excised from the gel and
digested with trypsin. Sequence analysis was performed upon the
trypsin-digested peptide by matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometry.
Production of Antibodies and Recombinant Proteins--
A plasmid
(pSK moesin) encoding full-length mouse moesin protein was obtained
from Dr. S. Tsukita (Kyoto University). To construct the GST fusion
proteins, the moesin DNA sequence was amplified by polymerase chain
reaction and subcloned into vector pGEX-4T-1 (Amersham Biosciences).
The construct was confirmed by DNA sequencing. GST fusion proteins were
expressed in DH5
cells and purified on glutathione-agarose beads. A
moesin polyclonal antibody was produced in rabbit against purified
GST-fused full-length mouse moesin. The antibody reacted only with
moesin, not with ezrin or radixin, and we have named the antibody TM2.
A polyclonal antibody against Thr-558-phosphorylated ERM proteins was
raised in rabbits against a KLH-conjugated synthesized phosphopeptide
(KYKpTLRQCCCCC, where pT is phosphothreonine) (peptide from
Genemed Synthesis; KLH from Pierce), which corresponded to the mouse
moesin sequence from amino acids 555-561. The resulting antibody
reacted with only phosphorylated ERM proteins but not unphosphorylated
ERM proteins.
Cell Culture and Transfection--
H19-7/IGF-IR cells were
obtained from the American Type Culture Collection (Manassas, VA) and
maintained in Dulbecco's modified Eagle's medium (DMEM) containing
10% fetal bovine serum, 200 µg/ml G418, and 1 µg/ml puromycin at
34 °C under 5% CO2. H19-7/IGF-IR cells were seeded at
2 × 105 in a 6-well plate coated with
poly-L-lysine. For glutamate treatment, the cells were
cultured in serum-free DMEM for 18 h and then stimulated with or
without 100 µM glutamate for various periods (2, 5, 10, 30, and 60 min). The transfection of plasmids (3.2 µg of pcDNA C3, pCMV-Myc RhoAV14, or empty vectors) into H19-7/IGF-IR cells was
carried out using LipofectAMINE 2000 reagent (Invitrogen) according to
the manufacturer's instructions. Transient overexpression of the
pCMV-Myc RhoAV14 proteins was verified by immunoblotting cell lysates
with an anti-Myc monoclonal antibody. The transient overexpression of
C3 transferase was detected by the mobility shift of ADP-ribosylated
endogenously expressed RhoA (26). The transfected cells were cultured
in serum-free DMEM for 20 h and then stimulated with or without
100 µM glutamate for 10 min. To examine the involvement
of Rho kinase in glutamate-induced moesin phosphorylation, we used a
Rho kinase inhibitor, Y-27632 (Tocris Cookson). Before the glutamate
treatments, 30 µM Y-27632 was incubated with serum-free
DMEM for 1 h in H19-7/IGF-IR cells
Rat1 and MDCK were cultured in DMEM supplemented with 10% fetal bovine
serum. For lysophosphatidic acid (LPA, Avanti Polar Lipids) treatment,
Rat1 cells were seeded at 4 × 105 cells in a 6-well
plate. The next day, the cells were serum-starved for 18 h in
serum-free DMEM. After adding LPA to a concentration of 1 µg/ml, the
cells were incubated for various periods (0, 2, 5, 10, and 30 min). For
phosphorylation analysis, H19-7/IGF-IR and Rat1 cells were fixed with
10% trichloroacetic acid, washed with phosphate-buffered saline
three times, and then solubilized with 100 µl of 1 × Laemmli's
sample buffer.
RhoA, Rac1, and Cdc42 Activity Assays--
RhoA, Rac1, and Cdc42
activities were measured according to the modified method of Ren
et al. (23). The H19-7/IGF-IR cells (2 × 107 cells) were seeded in 100-mm culture dishes and
serum-starved in serum-free DMEM for 18 h before lysis. The cells
were then treated with or without 100 µM glutamate. For a
RhoA activity assay, the cells were lysed with ice-cold buffer (25 mM Tris, pH 7.5, 250 mM NaCl, 5 mM
MgCl2, 1 mM sodium orthovanadate, 0.25% sodium
deoxycholate, 0.05% SDS, 0.5% Triton X-100, 1 mM PMSF, 1 mM DTT, 1 µg/ml aprotinin, and 1 µg/ml leupeptin) for
15 min on ice. The cell lysates were then passed 10 times through a
23-gauge needle and centrifuged at 10,000 × g for 10 min at 4 °C. The supernatants were incubated with 30 µg of
glutathione-Sepharose beads bound to the GST-RhoA-binding domain of
mouse rhotekin for 60 min at 4 °C. For Rac1 or Cdc42 activity
assays, the cells were resuspended in 200 µl of NS buffer (25 mM Tris, pH 7.5, 1.5 mM MgCl2, 1 mM sodium orthovanadate, 1 mM PMSF, 1 µg/ml
aprotinin, and 1 µg/ml leupeptin) for 10 min on ice and then passed
10 times through a 25gauge needle. After the addition of 200 µl of
2× no-salt lysis buffer (50 mM Tris, pH 7.5, 10 mM MgCl2, 2% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM PMSF, 1 µg/ml aprotinin, and 1 µg/ml leupeptin), the cell lysate was passed through a 23G needle 10 times and placed on ice for 5 min, and then 400 µl of high
salt-binding buffer (25 mM Tris, pH 7.5, 30 mM
MgCl2, 100 mM NaCl, 0.5% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM PMSF, 1 µg/ml
aprotinin, and 1 µg/ml leupeptin) were added, and the cell lysates
were centrifuged at 10,000 × g for 10 min at 4 °C.
The supernatants were incubated with 30 µg of glutathione-Sepharose
beads bound to the GST-Rac/Cdc42-binding domain of rat PAK3 (GST-PBD)
for 60 min at 4 °C. The beads were washed three times with
wash buffer (25 mM Tris, pH 7.5, 40 mM NaCl, 30 mM MgCl2, 1% Nonidet P-40, and 1 mM DTT). The bound proteins were eluted in Laemmli's
sample buffer, separated by 15% SDS-PAGE, and analyzed by
immunoblotting with mouse monoclonal anti-RhoA, anti-Rac1, and
anti-Cdc42 antibodies.
Subcelluar Fractionation--
To obtain cytosolic and membranous
fractions, Rat1 cells were rinsed once in cold phosphate-buffered
saline and then lysed in detergent-free buffer (25 mM Tris,
pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM DTT, 1 µg/ml aprotinin, and 1 µg/ml leupeptin) by
passing 10 times through a 25 gauge needle. The lysed cells were
pelleted at 100,000 × g for 1 h. The supernatants
were used as cytosol, and the pellets as crude membrane. The samples
were added with sample buffer (3×) and incubated at 100 °C for 5 min.
 |
RESULTS |
Purification and Identification of the 75-kDa Phosphoprotein in the
Rat Hippocampus--
Previously we reported that ECS induces CREB
phosphorylation in the rat hippocampus (6). To identify the kinases
responsible for the phosphorylation of CREB in the rat hippocampus
after ECS, we studied the phosphorylation of Rsk, a cytosolic protein
kinase for ribosomal S6, which was reported as a CREB kinase in glial cell progenitors (24). Initially, we examined the mobility shifts of
Rsks after ECS in the rat hippocampus and could observe the mobility
shifts (data not shown). We then examined the phosphorylation status of
S6K in the rat brain after ECS using an anti-phospho-p70 S6K antibody.
S6K was highly phosphorylated in the rat hippocampus before
stimulation, and we were unable to find any further S6K phosphorylation
(Fig. 1, arrowhead). However,
we found that this antibody cross-reacted with five more bands (Fig.
1), and three of these showed density changes after ECS
(upper, middle, and lower
arrows). The antibody against S6K itself did not detect any
protein bands coincident with these three proteins, indicating that
these proteins might not be directly related to S6K. Because the
phospho-specific antibody was generated against the serine- and
threonine-phosphorylated peptide of S6K, we presumed that the increase
in band intensities suggested the increased phosphorylation of serine
and/or threonine residues in these proteins. Of the three
bands, we focused on the middle protein, which was a doublet of 75 and
80 kDa. The phosphorylation of the doublet was so rapid that it only
lasted 1 min after ECS in the rat hippocampus (Fig. 1).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Immunoblot analysis with the anti-phospho-p70
S6 kinase antibody of rat hippocampal lysate after ECS. After ECS,
rats were sacrificed at prescribed times. The hippocampi were separated
on ice and homogenized immediately in 10 volumes of homogenization
buffer. Tissue lysates were fractionated in 8% SDS-PAGE, transferred
to a nitrocellulose membrane, and then immunoblotted with an
anti-phospho-p70 S6 kinase antibody. Molecular size standards are shown
on the left. S, sham-treated animal.
|
|
To identify the protein, we purified it from the brain lysates of
ECS-treated rats (1 min after ECS) using the six-step procedure described under "Experimental Procedures." During the purification steps, we lost the 80-kDa protein and, therefore, were only able to
purify the 75-kDa protein to homogeneity (Fig.
2A, left panel). Because we traced the 75-kDa protein during the purification procedures by immunoblotting, we were unable to estimate purification fold and
yield. Coomassie staining of the final preparation revealed two protein
bands, a major band with molecular size of 75 kDa and a minor
smaller molecular size band. These two proteins both reacted with the
anti-phospho-p70 S6K antibody, and their band intensities coincided
with the protein amounts (Fig. 2A, right panel),
suggesting that the smaller protein might be a proteolytic product of
the major protein. The major band was eluted from the gel and digested
with trypsin. The masses of the tryptic peptides were measured by
MALDI-TOF. The masses of 10 peptides were analyzed using a data base
search program (NCBInr 02.15.00), and it was found that seven of these
peptides matched those of rat moesin (data not shown). To confirm
whether the purified 75-kDa protein was really a moesin, the purified
protein was immunoblotted with a commercially available monoclonal
antibody against human moesin (Figs. 2 and 4,
-ME). This
antibody reacted with the lower band as well as the upper band, and the
intensities corresponded well with the amount of purified protein (Fig.
2B, left panel). Although we did not identify the
lower band of purified proteins by peptide analysis, these results
imply that the lower band may have been caused by a cleavage of moesin
during the purification.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
Purification and identification of the 75-kDa
protein as moesin. A, purified 75-kDa protein was
electrophoresed in 8% SDS-PAGE and stained with Coomassie Blue
(left panel) or immunoblotted with
anti-phospho-p70 S6 kinase antibody (right
panel). B, purified protein was electrophoresed,
transferred to a membrane, and immunoblotted with anti-moesin
monoclonal ( -ME), anti-phosphoserine
( -p-Ser) or anti-phosphothreonine ( -p-Thr)
antibodies. C, 1 min after ECS or sham treatment the rats
were sacrificed, and moesin was immunoprecipitated from the hippocampal
lysates with the anti-moesin monoclonal antibody. The
immunoprecipitates were fractionated by SDS-PAGE, immunoblotted with
anti-phosphoserine and anti-phosphothreonine antibodies, and then
stripped and reprobed with an anti-moesin polyclonal antibody
( -MR) as a protein content control. S,
sham-treated animal; E1, 1 min after ECS. The results are
representative of three independent experiments.
|
|
Moesin Phosphorylation at Serine and Threonine in the Rat
Hippocampus after ECS--
After the purified protein had been
identified as moesin, we examined the phosphorylation of the purified
moesin. Because the anti-phospho-p70 S6K antibody we used was produced
against a synthetic peptide dually phosphorylated at the Thr-421 and
Ser-424 residues of S6K, we examined the phosphorylation of the serine and threonine residues of the purified moesin with the
anti-phosphoserine and anti-phosphothreonine antibodies. Both
the anti-phosphoserine and anti-phosphothreonine antibodies reacted
with the purified moesin, indicating that the purified moesin was
phosphorylated at both the serine and threonine residues (Fig.
2B, middle and right panels). Because
the brain lysate used for the purification of the 75-kDa protein was
prepared from rats 1 min after ECS, the results suggested that ECS
might increase the phosphorylation of moesin in the rat hippocampus. To
determine whether this was the case, the moesin in the
hippocampal lysates of sham and ECS-treated (1 min) rats were
immunoprecipitated with anti-moesin monoclonal antibody and
immunoblotted with polyclonal anti-phosphoserine and
anti-phosphothreonine antibodies. We confirmed that the
phosphorylation of moesin at both the serine and threonine residues
indeed increased in the rat hippocampus 1 min after ECS (Fig.
2C).
Phosphorylation of Moesin at Thr-558 in the Rat Hippocampus after
ECS--
Having confirmed that the purified moesin from rat brain was
phosphorylated at its serine and threonine residues, we examined the
phosphorylation of moesin at Thr-558 in the rat hippocampus after ECS.
Thr-558 is a well known phosphorylation site of moesin and is shared by
other ERM protein family members (Thr-567 in ezrin and Thr-564 in
radixin). The rat hippocampal lysates after ECS were examined with the
phospho-Thr-558-specific antibody 297S (kindly provided by Professor
Tsukita), which can detect all three phosphorylated ERM proteins. The
antibody 297S detected at least five proteins in the rat hippocampal
lysate. Three protein bands had molecular sizes bigger than 100 kDa,
suggesting that these proteins were not ERM proteins and were detected
nonspecifically. The molecular sizes of the other two protein bands,
which showed density increases after ECS in accordance with those of
the phosphoprotein bands in rat hippocampus detected by the
anti-phospho-S6K antibody after ECS, were estimated to be 75 and 82 kDa
(Fig. 3A), suggesting that
these phosphoproteins were moesin and radixin, respectively. To confirm
this, we immunoblotted the deprobed membrane with a polyclonal
anti-moesin antibody, which was capable of reacting with moesin and
radixin (Figs. 2 and 3,
-MR). The polyclonal anti-moesin
antibody detected two bands in the hippocampal lysate, which
corresponded to the major and minor bands detected by the phospho-specific antibody, 297S. These results showed that ECS increased the phosphorylation of two of the ERM proteins in the rat
hippocampus, namely moesin and radixin (but primarily moesin) and that
the phosphorylation of these proteins was rapid and transient, peaking
at 1 min (4-fold that of the basal level) and returning to the base
line 2 min after ECS (Fig. 3B). Because moesin was the major
phosphorylated ERM protein in the rat hippocampus and the
phosphoprotein we had purified from rat brain after ECS, we decided to
focus on moesin phosphorylation.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 3.
Moesin phosphorylation at Thr-558 in the rat
hippocampus after ECS. A, after ECS, rats were
sacrificed at prescribed times. The hippocampi were separated on ice
and homogenized immediately in 10 volumes of homogenization buffer.
Tissue lysates were fractionated in SDS-PAGE, transferred to a
nitrocellulose membrane, and then immunoblotted with anti-phospho-Thr
ERM ( -297S, top) or anti-moesin
( -MR, bottom) antibodies. The
arrowhead indicates the phosphoprotein bands detected by
297S, which coincided with those detected by the anti-moesin antibody.
S, sham-treated animal. B, the intensity of
phosphorylated and total moesin bands in A was quantitated
by densitometric analysis, and the amounts of phosphorylated moesin
were normalized to the amounts of total moesin. The data shown
represent the means ± S.E. of three independent
experiments.
|
|
Production of Anti-moesin and Thr-558-phosphorylated
Moesin-specific Antibodies--
To obtain the moesin-specific
antibody, the purified full length of mouse moesin fused to GST was
injected subcutaneously into two rabbits. As shown in Fig.
4A, the polyclonal antibody raised against whole moesin (designated as TM2) reacted only with moesin even in MDCK cells (which expressed large amounts of ezrin) and
did not cross-react with ezrin or radixin, whereas the monoclonal antibody moesin (Figs. 2 and 4,
-ME) detected two protein
bands with molecular sizes of 75 and 85 kDa, which were moesin and
ezrin, respectively (Fig. 4A).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
Production of moesin and
Thr-558-phosphorylated moesin-specific antibodies. A,
to examine the specificity of the moesin antibody, the total cell
lysates of Rat1 cells (lane 1), MDCK cells
(lane 2), and H19-7/IGF-IR cells
(lane 3) were electrophoresed in parallel
SDS-PAGE and analyzed by immunoblotting with anti-moesin
( -TM2 or -ME) antibodies; the
upper arrow indicates ezrin and the
lower arrow indicates moesin. B, to
test the specificity of the phospho-ERM antibody
( -p-ThrERM) against the C-terminal threonine 558 of
moesin, membrane and cytosolic fractions from serum-starved Rat1 cells
were electrophoresed in SDS-PAGE and analyzed by immunoblotting with
anti-p-ThrERM or TM2 antibodies. The anti-p-ThrERM antibody reacts with
moesin in the membrane fraction, which is of the phosphorylated form.
C, serum-starved Rat1 cells were unstimulated or stimulated
with LPA, and after 0, 2, 5, 10, or 30 min of incubation whole cell
lysates were electrophoresed in SDS-PAGE and analyzed by immunoblotting
with anti-p-ThrERM or TM2 antibodies. C, unstimulated Rat1
cells.
|
|
In addition, we produced a phospho-ThrERM (p-ThrERM)-specific antibody.
The polyclonal antibody p-ThrERM was raised in rabbits against the
KLH-conjugated synthesized phosphopeptide (KYKpTLRQCCCCC) corresponding
to the mouse moesin sequence from amino acids 555-561, which is shared
by all three ERM proteins.
To test the reactivity and specificity of this antibody, the lysates of
Rat1 cells were immunoblotted after LPA stimulation. A protein band
detected by the anti-p-ThrERM antibody increased in intensity 2 min
after LPA stimulation, and this was sustained up to 30 min (Fig.
4C). The molecular size of the detected band was 75 kDa, and
this coincided well with moesin when the blot was reprobed with the
moesin antibody TM2. The temporal pattern of increased moesin
phosphorylation was similar to that reported previously (17, 19),
indicating that the phospho-specific antibody detected the
Thr-558-phosphorylated form of moesin. To ensure that this
phospho-Thr-558-specific antibody was specific for
Thr-558-phosphorylated moesin and did not cross-react with unphosphorylated moesin, we immunoblotted the membrane and the cytosolic fractions of Rat1 cell lysates with p-ThrERM and TM2 antibodies. It was found that the phosphorylated moesin localized only
to the membrane fraction. Because the antibody did not detect any
protein in the cytosolic fraction of Rat1 cells despite the existence
of a substantial amount of moesin (Fig. 4B), we concluded that the antibody specifically reacted with the Thr-558-phosphorylated moesin. Even though all the ERM proteins share this peptide sequence containing phosphorylated threonine, the polyclonal p-ThrERM antibody detected only one band in the Rat1 cell lysate. This result
suggests that moesin might be the predominant ERM protein in the Rat1
cell. Another possibility was that the phosphorylated statuses of
radixin and ezrin in the Rat1 cell might be comparatively low. To
address this point, we determined the amounts of ERM proteins in Rat1 cells. Indeed, moesin was found to predominate in Rat1 cells (Fig. 4A). To confirm that the anti-p-ThrERM antibody could detect
other phosphorylated ERM proteins, we immunoblotted MDCK cell lysate and observed phosphorylated ezrin and moesin (data not shown).
Glutamate Induces Thr-558 Phosphorylation of Moesin in
H19-7/IGF-IR Cells--
Previously, it was reported (24) that
tonic-clonic seizure after ECS induced the release of neurotransmitters
in the rat hippocampus. Therefore, there is a possibility that ECS may
induce the phosphorylation of moesin through the release of
neurotransmitters, so we studied whether glutamate could induce the
phosphorylation of moesin in H19-7/IGF-IR-immortalized rat hippocampal
progenitor cells. The anti-p-ThrERM antibody detected only one band in
the lysate of the H19-7/IGF-IR cells, and this band corresponded to moesin. Like Rat1 cells, moesin was the predominant ERM protein in
H19-7/IGF-IR cells, and the levels of ezrin and radixin were very low
(Fig. 4A). The Thr-558 of moesin was phosphorylated in H19-7/IGF-IR cells even without glutamate stimulation, as has been
described previously (16), but glutamate treatment rapidly increased
moesin phosphorylation at Thr-558. This phosphorylation level was
doubled in 2 min, was sustained to 30 min, and then declined slowly to
reach the base line 60 min after glutamate treatment (Fig.
5, A and B).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 5.
Glutamate-induced phosphorylation of moesin
at Thr-558 in H19-7/IGF-IR cells. A, serum-starved
H19-7/IFGR cells were unstimulated or stimulated with 100 µM glutamate, and at 2, 5, 10, 30, or 60 min of
incubation whole cell lysates were electrophoresed in SDS-PAGE and
analyzed by immunoblotting with anti-p-ThrERM ( -p-ThrERM)
or TM2 ( -TM2) antibodies. B, the intensity of
phosphorylation and total moesin bands in A was quantitated
by densitometric analysis, and the amounts of phosphorylated moesin
were normalized to the amounts of total moesin. The data represent the
means ± S.E. of four independent experiments. C,
unstimulated H19-7/IGF-IR cells.
|
|
RhoA and Rho kinase Are Involved in the Phosphorylation of Moesin
by Glutamate--
The Rho family proteins RhoA, Rac1, and Cdc42 have
been implicated in the phosphorylation of moesin in various cell lines. To determine whether the activation of RhoA, Rac1, or Cdc42 is involved
in the phosphorylation of moesin at Thr-558, we examined the activities
of RhoA, Rac1, or Cdc42 in H19-7/IGF-IR cells after glutamate
treatment by measuring the amounts of RhoA bound to the GST-fused
RhoA-binding domain of rhotekin (GST-RBD) or Rac1/Cdc42 bound to the
GST-fused Rac/Cdc42-binding domain of PAK3 (GST-PBD). Glutamate induced
a rapid increase in the amount of cellular GTP-bound RhoA in
H19-7/IGF-IR cells but did not increase in the amount of cellular
GTP-bound Rac1 (Fig. 6, A and
B). The amount of GTP-bound Cdc42 was barely detectable in
H19-7/IGFR-IR cells even after glutamate treatment, suggesting that
the activity of Cdc42 in this hippocampal progenitor cell line was very
low and not increased by glutamate treatment (data not shown). These
results indicate that glutamate activates RhoA, not Rac1 or Cdc42, in
the rat hippocampal neuronal cell H19-7/IGF-IR. The activity of RhoA
peaked at 2 min (265% average) and was sustained 10 min after
glutamate treatment, which preceded the phosphorylation of moesin at
Thr-558, suggesting that RhoA might be involved in the phosphorylation
of moesin at Thr-558. To determine whether the inactivation of RhoA
might inhibit glutamate-induced moesin phosphorylation, we transiently
transfected expression plasmids carrying the C3 cDNA, which encodes
a potent inhibitor of RhoA (C3 transferase) (25) or an empty vector
into H19-7/IGF-IR cells. The glutamate-induced moesin phosphorylation was significantly suppressed in the presence of C3 toxin. Because C3
transferase catalyzes the ADP-ribosylation of RhoA on asparagine 41, we
examined the mobility of RhoA in C3-transfected hippocampal neuronal cells to confirm that the C3 transferase acted properly. As
shown in Fig. 7B, the mobility
of RhoA was retarded in C3-transfected H19-7/IGF-IR cells, indicating
that RhoA was ADP-ribosylated. Because the suppression of the
phosphorylation of moesin by RhoA C3 inhibition indicated that RhoA was
involved in the phosphorylation of moesin in H19-7/IGF-IR cells after
glutamate stimulation, as a next step we investigated whether activated
RhoA might be sufficient for the phosphorylation of moesin in neuronal
cells. Expression plasmids encoding Myc epitope-tagged activated RhoA
(RhoAV14) were transfected into H19-7/IGF-IR cells. The cells were
then serum-starved and lysed for immunoblotting. The basal level of moesin phosphorylation at Thr-558 was increased 2-fold in
RhoAV14-transfected H19-7/IGF-IR cells versus that of
non-transfected cells, indicating that activated RhoA can increase the
phosphorylation of moesin at Thr-558. The expression of RhoAV14 was
confirmed by the detection of tagged Myc by using an anti-Myc antibody
(Fig. 7C).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 6.
Glutamate-induced RhoA activation.
A, serum-starved H19-7/IFGR cells were unstimulated or
stimulated with 100 µM glutamate, and after 2, 5, 10, 30, or 60 min of incubation whole cell lysates were incubated with GST-RBD
or GST-PBD, and the amounts of GTP-bound RhoA (GTP-RhoA) or
Rac1 (GTP-Rac1), respectively, were determined by
immunoblotting with anti-RhoA or Rac1 antibodies. Total amounts of RhoA
and Rac1 in the cell lysates are also shown. B, the
intensities of GTP-bound RhoA and Rac1 were normalized to the amounts
of RhoA and Rac1 in the whole cell lysates, respectively. The data
shown represent the means ± S.E. of three independent
experiments.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
RhoA is involved in the phosphorylation of
moesin by glutamate. A, the suppression of
glutamate-induced moesin Thr-558 phosphorylation by C3 transferase.
Empty vector DNA (Vector)- or pcDNA C3
(C3)-transfected serum-starved cells were unstimulated or
stimulated with 100 µM glutamate for 10 min, and whole
cell lysates were electrophoresed in SDS-PAGE and analyzed by
immunoblotting with anti-p-ThrERM ( -p-ThrERM) or TM2
( -TM2) antibodies. Densitometric analysis was performed,
and the data shown represent the means ± S.E. of four independent
experiments. B, immunoblot detection of RhoA
(lower arrow) and ADP-ribosylated RhoA
(upper arrow) with the anti-RhoA antibody
( -RhoA) in lysates of H19-7/IGF-IR cells transfected
with pcDNA empty vector or pcDNA C3 plasmids. C, an
increase in the level of phosphorylated moesin by RhoAV14 is shown.
H19-7/IGF-IR cells were transfected with pCMV-Myc RhoAV13 DNA
(RhoAV14) or empty vector (Vector). Cells were
then serum-starved and whole cell lysates were electrophoresed in
SDS-PAGE and analyzed by immunoblotting with anti-p-ThrERM or TM2
(top and middle panels). The presence
of RhoAV14 increased the basal level of moesin Thr-558 phosphorylation
2-fold in H19-7/IGF-IR cells. To ensure RhoAV14 expression, the blot
was immunoblotted with an anti-Myc antibody (bottom
panel). The results shown are representative of three
independent experiments.
|
|
Among the downstream effectors of RhoA, Rho kinase has been reported to
be involved in the phosphorylation of moesin in various non-neuronal
cell lines. Therefore, we examined glutamate-induced moesin
phosphorylation in H19-7/IGF-IR cells after pretreating with the Rho
kinase inhibitor Y-27632. The moesin phosphorylation induced by
glutamate treatment was completely suppressed in the presence of 30 µM Y-27632 (Fig. 8,
A and B), suggesting that Rho kinase was involved
in the phosphorylation of moesin at Thr-558. Although the inhibition of
RhoA and Rho kinase abolished the phosphorylation of moesin at Thr-558
in H19-7/IGF-IR cells induced by glutamate, its inhibitory effect did
not change the basal level of moesin phosphorylation, suggesting that
there might be pathways of moesin phosphorylation not involving RhoA
and Rho kinase. This was the same picture that emerged in the brain.
ECS rapidly induced the phosphorylation of moesin in the rat
hippocampus, but we also observed a basal phosphorylation of moesin.
Further studies will be needed to elucidate the pathways involved in
the basal phosphorylation of moesin at Thr-558 in H19-7/IGF-IR
cells.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 8.
Inhibition of moesin Thr-558 phosphorylation
by Rho kinase inhibitor. A, serum-starved H19-7/IGF-IR
cells were pre-incubated with the Rho kinase inhibitor Y-27632 (60 min,
30 µM) and then unstimulated or stimulated with 100 µM glutamate for 10 min. Whole cell lysates were
electrophoresed by SDS-PAGE and analyzed by immunoblotting with
anti-p-ThrERM ( -p-ThrERM) or TM2 ( -TM2)
antibodies. A Rho kinase inhibitor suppressed the glutamate-induced
moesin phosphorylation. B, densitometric analysis was
performed, and the data shown represent the means ± S.E. of four
independent experiments.
|
|
 |
DISCUSSION |
In the present study, we demonstrate that ECS induced the
phosphorylation of moesin at Thr-558 in the rat hippocampus. The phosphorylation and activation of signaling molecules in
vivo is not easy to study because it is difficult to find
effective stimuli for tissues or organs. We have used ECS as a unique
stimulus for the study of signaling molecule activation and the
induction of genes in brain tissues. We have reported previously the
activation of the Pyk2-Ras-Raf-MEK-ERK cascade and the activation of
other signaling molecules such as CREB and stress kinases in the rat hippocampus after ECS (2, 3, 5-7). However, the mechanism of
activation of these signaling molecules remains unknown. We assumed
that glutamate, known to be released after ECS and/or depolarization
induced by electricity, may be involved in the activation of these
signaling molecules. Based on this assumption, we used a hippocampal
progenitor cell H19-7/IGF-IR to study the effects of glutamate on the
phosphorylation of moesin. Indeed, the glutamate treatment did induce
the phosphorylation of moesin at Thr-558 in H19-7/IGF-IR cells,
suggesting the possibility that ECS may induce the phosphorylation of
moesin by the release of glutamate in the rat hippocampus. However, the
temporal pattern of moesin phosphorylation by ECS in the rat
hippocampus was quite different from that found for glutamate in
H19-7/IGF-IR cells. Moesin phosphorylation was very rapid and
transient in the rat hippocampus; it immediately increased after ECS
and returned to the basal level after 2 min, whereas the
phosphorylation lasted for 30 min after glutamate treatment in
H19-7/IGF-IR cells. This kind of discrepancy was observed even in the
activation of other signaling molecules such as ERKs. The
phosphorylation of ERKs in the rat hippocampus by ECS was rapid and
transient and returned to a basal level 5 min after ECS, whereas
the activation of ERKs in rat hippocampal slice cultures lasted longer
(3, 27). The reasons for these discrepancies are unknown, but they
indicate that the activation and inactivation of signal transduction
systems in the live brain are more dynamic than that in in
vitro cultured cells.
ERM proteins are activated by C-terminal threonine phosphorylation,
which maintains ERM proteins in an active state by suppressing intramolecular interactions (28). These proteins play a crucial role in the formation of microvilli, cell-to-cell adhesion, the maintenance of cell shape, cell motility, and membrane trafficking. Recent analyses have shown that ERM proteins are not only involved in
the cytoskeletal organization but are also involved in signaling pathways. In neuronal cells, moesin and radixin are reported to be
important for growth cone development and maintenance (29). However,
the functional role of ERM proteins as well as their phosphorylation in
mature neurons has not been elucidated. In this study, for the first
time, we showed that the ERM protein moesin was phosphorylated in the
rat hippocampus by ECS and that glutamate can induce the
phosphorylation of moesin at Thr-558 by activating RhoA and Rho kinase.
However, we have not studied the functional role of phosphorylated
moesin. Thus, it remains to be elucidated whether phosphorylated moesin
is also involved in the cytoskeletal organization of neuronal cells
and/or other signaling pathways in neuronal tissues.
Although many cultured cells express all three ERM proteins, the
amounts of ERM proteins widely vary from cell to cell. In epithelial
cells, ezrin expression is much higher than moesin or radixin, and
moesin is reported to predominate among ERM proteins in endothelial
cells. In neuronal cells, moesin is highly expressed in PC12 cells and
glioma cells, whereas the three ERM proteins are equally expressed in
astrocytes (30-32). In the rat hippocampus and hippocampal progenitor
cells, moesin predominated (Figs. 2A and 4A).
Thus, moesin is the major phosphorylated ERM protein in the rat
hippocampus after ECS and in H19-7/IGF-IR cells after glutamate
treatment. In primary cultured neurons, moesin and radixin but not
ezrin regulate growth cone development and cell motility (29). Thus, it
seems likely that moesin and radixin are needed for neuronal
development and that moesin may be the major ERM protein in terms of
neuronal development.
It has been reported that the expression of constitutively active
mutants of members of the small GTPase family, Rho, Rac, and Cdc42,
induce phosphorylation on the C-terminal threonine residue of ERM
proteins (33). In the present study, we found that glutamate
transiently activates only RhoA and not Rac1 or Cdc42 in H19-7/IGF-IR
cells and that the inhibition of RhoA resulted in the suppression of
moesin phosphorylation induced by glutamate. Our results suggest that
RhoA activation is involved in the phosphorylation of moesin at Thr-558
in hippocampal progenitor cells. Previously, LPA-induced RhoA
activation was reported to induce the threonine phosphorylation of
moesin and changes in the actin-based cytoskeleton of fibroblast cells
(17). However, we did not observe any changes in either the morphology
or the actin-based cytoskeleton in H19-7/IGF-IR cells after glutamate
treatment (data not shown), which suggests that the activated RhoA in
H19-7/IGF-IR cells may not induce cytoskeletal changes. In neuronal
cells, the Rho signaling pathway has classically been implicated in
axonal outgrowth, dendrogenesis, cell migration during neural
development, exocytosis, and endocytosis (34). In addition, the Rho
effector protein citron forms a heteromeric complex with PSD-95 and
N-methyl-D-aspartate receptors and is concentrated at postsynaptic sites in hippocampal neurons (35). Although the functional roles of citron have not been defined, previous
reports suggest its involvement in the synaptic function. Taken
together, it is possible that glutamate-induced RhoA activation and
activated RhoA-mediated phosphorylation of moesin in the rat hippocampus and neuronal cells may affect cellular functions other than
cytoskeleton changes, such as synaptic vesicle recycling or glutamate
receptor endocytosis. Thus, studies on the exact intracellular
localizations of moesin and its phosphorylated form and on the proteins
bound to them are needed to elucidate the function of moesin in
neuronal cells.
Thr-558 of moesin was reported to be effectively phosphorylated
in vitro by Rho kinase, phosphatidylinositol-4-phosphate
5-kinase, PKC-
, and myotonic dystrophy kinase-related Cdc42-binding
kinase (17, 21, 33, 36). However, the kinases for moesin
phosphorylation in vivo remain controversial. Originally,
Rho kinase was suggested to be a downstream kinase for the
phosphorylation of ERM proteins by a constitutively active form of RhoA
in Swiss 3T3 cells (37), and this was supported by the phosphorylation
of moesin by the dominant Rho kinase in transfected COS cells (21).
However, Rho kinase phosphorylated myosin light chain and not ERM
proteins in glioma cells (38), and Matsui et al.
(28) reported that the inhibition of phosphatidylinositol-4-phosphate
5-kinase, rather than Rho kinase, eliminated the threonine
phosphorylation of ERM proteins in NIH 3T3 cells by LPA stimulation. It
is not clear whether this discrepancy was caused by differences in the
cell lines used for these studies. In the present study, the
phosphorylation of moesin at Thr-558 by glutamate treatment in
hippocampal progenitor cells was completely suppressed by the
inhibitory effect of Rho kinase, which indicates that the
phosphorylation is mediated by Rho kinase in this neuronal cell line.
Taken together, our results show that the phosphorylation of moesin at
Thr-558 in hippocampal progenitor cells (H19-7/IGF-IR) by glutamate
treatment is mediated by RhoA and Rho kinase. However, we do not
exclude the possibility that kinases other than RhoA and Rho kinase may
be involved in the phosphorylation of moesin in hippocampal neuronal
cells. We observed a basal level of moesin phosphorylation in
H19-7/IGF-IR cells and in the rat hippocampus. Moreover, this basal
level of phosphorylation in H19-7/IGF-IR cells was not affected by the
inhibition of RhoA or Rho kinase, suggesting that kinases other than
Rho kinase are involved in the phosphorylation of moesin and that the
activities of these other kinases are not affected by glutamate
treatment. We will continue studying to identify those kinases
responsible for the basal level of moesin phosphorylation in
hippocampal neuronal cells.
In the present study, we identified the phosphorylation of moesin in
the rat hippocampus after ECS with the anti-phospho-S6K antibody, which
suggests a possible sequence homology between the amino acid sequences
around the Thr-558 of moesin and those around the dual phosphorylation
site, Thr-421 and Ser-424 of S6K. However, the examination of amino
acid sequences revealed no homology between these two sequences,
indicating that the detection of moesin phosphorylation by
anti-phospho-S6K antibody was nonspecific and not amino acid sequence related.
We also observed the phosphorylation of serine residue(s) in the
purified moesin from the rat brain. The phosphorylation of ERM proteins
at the serine residue(s) has been reported but not extensively studied.
As yet, the phosphorylated serine residue(s) of ERM proteins and the
signaling system involved in the phosphorylation of the serine
residue(s) remain unknown. Although ECS increased the phosphorylation
at the serine residue(s) of moesin, we did not observe serine
phosphorylation in moesin in H19-7/IGF-IR cells after glutamate
treatment (data not shown). The intensities of the stimuli may explain
the difference. The increase of moesin phosphorylation in the rat
hippocampus by ECS was at least twice that observed in H19-7/IGF-IR
cells by glutamate. Therefore, glutamate stimulation may not be strong
enough to induce the phosphorylation of moesin at serine residue(s),
and a second stimulus such as depolarization may be needed to activate
the signaling system for the phosphorylation of moesin at serine
residue(s) in the rat brain. Further studies on the phosphorylation of
ERM proteins at serine residue(s) are needed to elucidate the mechanism
of serine phosphorylation in moesin.
In conclusion, we demonstrate the phosphorylation of moesin at Thr-558
by ECS in the rat hippocampus and by glutamate treatment in the
hippocampal progenitor cells H19-7/IGF-IR. Glutamate also activated
RhoA in H19-7/IGF-IR cells, and this moesin phosphorylation was
mediated by RhoA and Rho kinase. To our knowledge, this is the first
report on the phosphorylation of moesin in neuronal tissues. However,
the signaling pathways involved in the activation of RhoA by glutamate
remain to be elucidated.
 |
ACKNOWLEDGEMENTS |
We thank Dr. S. Tsukita of Kyoto University
for providing anti-phospho-ThrERM (297S) antibody and pSK-moesin and
Dr. Kozo Kaibuchi of Nagoya University for Y-27632 and HA1077. Anti-Myc antibody was kindly provided by Prof. M. Han of Sungkyunkwan University.
 |
FOOTNOTES |
*
This work was supported by Samsung Biomedical Research
Institute Grant B-98-022, the Research Fund of Sungkyunkwan University School of Medicine, and Ministry of Health and Welfare Grant
HMP-98-N-1-0009.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
82-31-299-6130; Fax: 82-31-299-6149; E-mail:
jbpark@med.skku.ac.kr.
Published, JBC Papers in Press, February 26, 2002, DOI 10.1074/jbc.M110380200
 |
ABBREVIATIONS |
The abbreviations used are:
ECS, electroconvulsive shock;
ERK, extracellular signal-regulated kinase;
MEK, mitogen-activated protein kinase/ERK kinase;
CREB, cAMP-response
element-binding protein;
S6K, ribosomal S6 kinase;
ERM, ezrin/radixin/moesin;
PMSF, phenylmethylsulfonyl fluoride;
DTT, dithiothreitol;
297S, anti-phospho-ERM antibody;
MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight mass
spectrometry;
GST, glutathione S-transferase;
TM2, a
polyclonal antibody that reacts only with moesin;
KLH, keyhole limpet
hemocyanin;
IGF-IR, human type I insulin-like growth factor receptor;
DMEM, Dulbecco's modified Eagle's medium;
MDCK, Madin-Darby canine
kidney cells;
LPA, lysophosphatidic acid;
RBD, RhoA-binding domain of
rhotekin;
PBD, Rac/Cdc42-binding domain of PAK3;
p-ThrERM, phospho-ThrERM;
RhoAV14, Myc epitope-tagged activated RhoA.
 |
REFERENCES |
| 1.
|
Fochtmann, L. J.
(1994)
Psychopharmacol. Bull.
30,
321-444[Medline]
[Order article via Infotrieve]
|
| 2.
|
Kang, U. G.,
Jeon, S. H.,
Lee, J. E.,
Joo, Y.-H., Yi, J. S.,
Park, J.-B.,
Juhn, Y.-S.,
and Kim, Y. S.
(2000)
Neuropharmacology
39,
703-706[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Kang, U. G.,
Hong, K. S.,
Jung, H. Y.,
Kim, Y. S.,
Seong, Y. S.,
Yang, Y. C.,
and Park, J. B.
(1994)
J. Neurochem.
63,
1979-1982[Medline]
[Order article via Infotrieve]
|
| 4.
|
Lee, Y. H.,
Ryu, S. H.,
Suh, P. G.,
Park, J. B.,
Ahn, Y. M.,
and Kim, Y. S.
(1993)
Biochem. Biophys. Res. Commun.
194,
665-670[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Oh, S. W.,
Ahn, Y. M.,
Kang, U. G.,
Kim, Y. S.,
and Park, J. B.
(1999)
Neurosci. Lett.
271,
101-104[CrossRef][Medline]
[Order article via Infotrieve].
|
| 6.
|
Jeon, S. H.,
Seong, Y. S.,
Juhnn, Y. S.,
Kang, U. G., Ha, K. S.,
Kim, Y. S.,
and Park, J. B.
(1997)
Neuropharmacology
36,
411-414[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Jeon, S. H., Oh, S. W.,
Kang, U. G.,
Ahn, Y. M.,
Bae, C. D.,
Park, J. B.,
and Kim, Y. S.
(2001)
Biochem. Biophys. Res. Commun.
282,
1026-1030[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Bretscher, A.,
Reczek, D.,
and Berryman, M.
(1997)
J. Cell Sci.
110,
3011-3018[Abstract]
|
| 9.
|
Tsukita, S.,
and Yonemura, S.
(1997)
Curr. Opin. Cell Biol.
9,
70-75[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Vaheri, A.,
Carpen, O.,
Heiska, L.,
Helander, T. S.,
Jaaskelainen, J.,
Majander-Nordenswan, P.,
Sainio, M.,
Timonen, T.,
and Turunen, O.
(1997)
Curr. Opin. Cell Biol.
9,
659-666[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
del Pozo, M. A.,
Nieto, M.,
Serrador, J. M.,
Sancho, D.,
Vicente-Manzanares, M.,
Martinez, C.,
and Sanchez-Madrid, F.
(1999)
Cell Adhes. Commun.
6,
125-133[Medline]
[Order article via Infotrieve]
|
| 12.
|
Mangeat, P.,
Roy, C.,
and Martin, M.
(1999)
Trends Cell Biol.
9,
187-192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Bretscher, A.
(1999)
Curr. Opin. Cell Biol.
11,
109-116[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Bretscher, A.
(1989)
J. Cell Biol.
108,
921-930[Abstract/Free Full Text].
|
| 15.
|
Krieg, J.,
and Hunter, T.
(1992)
J. Biol. Chem.
267,
19258-19265[Abstract/Free Full Text]
|
| 16.
|
Nakamura, F.,
Amieva, M. R.,
and Furthmayr, H.
(1995)
J. Biol. Chem.
270,
31377-31385[Abstract/Free Full Text]
|
| 17.
|
Matsui, T.,
Maeda, M.,
Doi, Y.,
Yonemura, S.,
Amano, M.,
Kaibuchi, K.,
Tsukita, S.,
and Tsukita, S.
(1998)
J. Cell Biol.
140,
647-657[Abstract/Free Full Text]
|
| 18.
|
Mackay, D. J.,
and Hall, A.
(1998)
J. Biol. Chem.
273,
20685-20688[Free Full Text]
|
| 19.
|
Shaw, R. J.,
Hary, M.,
Solomon, F.,
and Jacks, T.
(1998)
Mol. Biol. Cell
9,
403-419[Abstract/Free Full Text]
|
| 20.
|
Mackay, D. J.,
Esch, F.,
Furthmayr, H.,
and Hall, A.
(1997)
J. Cell Biol.
138,
927-938[Abstract/Free Full Text]
|
| 21.
|
Oshiro, N.,
Fukata, Y.,
and Kaibuchi, K.
(1998)
J. Biol. Chem.
273,
34663-34666[Abstract/Free Full Text]
|
| 22.
|
Gonzalez-Agosti, C.,
and Solomon, F.
(1996)
Cell Motil. Cytoskeleton
34,
122-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Ren, X. D.,
Kiosses, W. B.,
and Schwartz, M. A.
(1999)
EMBO J.
18,
578-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Pende, M.,
Fisher, T. L.,
Simpson, P. B.,
Russell, J. T.,
Blenis, J.,
and Gallo, V.
(1997)
J. Neurosci.
17,
1291-1301[Abstract/Free Full Text]
|
| 25.
|
Rowley, H. L.,
Martin, K. F.,
and Marsden, C. A.
(1995)
Neuroscience
68,
415-422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Aktories, K.,
and Hall, A.
(1989)
Trends Pharmacol. Sci.
10,
415-418[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Baron, C.,
Benes, C.,
Van Tan, H.,
Fagard, R.,
and Roisin, M. P.
(1996)
J. Neurochem.
66,
1005-1010[Medline]
[Order article via Infotrieve]
|
| 28.
|
Matsui, T.,
Yonemura, S.,
and Tsukita, S.
(1999)
Curr. Biol.
9,
1259-1262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Paglini, G.,
Kunda, P.,
Quiroga, S.,
Kosik, K.,
and Caceres, A.
(1998)
J. Cell Biol.
143,
443-455[Abstract/Free Full Text]
|
| 30.
|
Berryman, M.,
Franck, Z.,
and Bretscher, A.
(1993)
J. Cell Sci.
105,
1025-1043[Abstract].
|
| 31.
|
Schwartz-Albiez, R.,
Merling, A.,
Spring, H.,
Moller, P.,
and Koretz, K.
(1995)
Eur. J. Cell Biol.
67,
189-198[Medline]
[Order article via Infotrieve]
|
| 32.
|
Amieva, M. R.,
and Furthmayr, H.
(1995)
Exp. Cell Res.
219,
180-196[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Nakamura, N.,
Oshiro, N.,
Fukata, Y.,
Amano, M.,
Fukata, M.,
Kuroda, S.,
Matsuura, Y.,
Leung, T.,
Lim, L.,
and Kaibuchi, K.
(2000)
Genes Cells
7,
571-581
|
| 34.
|
Van Aelst, L.,
and D'Souza-Schorey, C.
(1997)
Genes Dev.
11,
2295-2322[Free Full Text].
|
| 35.
|
Zhang, W.,
Vazquez, L.,
Apperson, M.,
and Kennedy, M. B.
(1999)
J. Neurosci.
19,
96-108[Abstract/Free Full Text]
|
| 36.
|
Pietromonaco, S. F.,
Simons, P. C.,
Altman, A.,
and Elias, L.
(1998)
J. Biol. Chem.
273,
7594-7603[Abstract/Free Full Text].
|
| 37.
|
Fukata, Y.,
Kimura, K.,
Oshiro, N.,
Saya, H.,
Matsuura, Y.,
and Kaibuchi, K.
(1998)
J. Cell Biol.
141,
409-418[Abstract/Free Full Text]
|
| 38.
|
Kosako, H.,
Yoshida, T.,
Matsumura, F.,
Ishizaki, T.,
Narumiya, S.,
and Inagaki, M.
(2000)
Oncogene
19,
6059-6606[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike